Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 303

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

IKZF1plusDefines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Open access
Stanulla, Martin, Dagdan, Elif, Zaliova, Marketa, Möricke, Anja, Palmi, Chiara, Cazzaniga, Giovanni, Eckert, Cornelia, te Kronnie, Geertruy, Bourquin, Jean-Pierre, Bornhauser, Beat, Koehler, Rolf, Bartram, Claus R., Ludwig, Wolf-Dieter, Bleckmann, Kirsten, Groeneveld-Krentz, Stefanie, Schewe, Denis, Junk, Stefanie V., Hinze, Laura, Klein, Norman, Kratz, Christian P., Biondi, Andrea, Borkhardt, Arndt, Kulozik, Andreas, Muckenthaler, Martina U., Basso, Giuseppe, Valsecchi, Maria Grazia, Izraeli, Shai, Petersen, Britt-Sabina, Franke, Andre, Dörge, Petra, Steinemann, Doris, Haas, Oskar A., Panzer-Grümayer, Renate, Cavé, Hélène, Houlston, Richard S., Cario, Gunnar, Schrappe, Martin, Zimmermann, Martin, for the TRANSCALL Consortium, the International BFM Study Group·2018·Journal of Clinical Oncology

Abstract

Purpose: Somatic deletions that affect the lymphoid transcription factor–coding gene IKZF1 have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognostic strength of IKZF1 deletions by analyzing the effect of co-occurring deletions. Patients and Methods: The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of findings involved 417 patients from the same trial. Results: IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion conferred the worst outcome and, consequently, were grouped as IKZF1 plus. The IKZF1 plus group comprised 6% of patients with BCP ALL, with a 5-year event-free survival of 53 ± 6% compared with 79 ± 5% in patients with IKZF1 deletion who did not fulfill the IKZF1 plus definition and 87 ± 1% in patients who lacked an IKZF1 deletion ( P ≤ .001). Respective 5-year cumulative relapse incidence rates were 44 ± 6%, 11 ± 4%, and 10 ± 1% ( P ≤ .001). Results were confirmed in the replication cohort, and multivariable analyses demonstrated independence of IKZF1 plus. The IKZF1 plus prognostic effect differed dramatically in analyses stratified by minimal residual disease (MRD) levels after induction treatment: 5-year event-free survival for MRD standard-risk IKZF1 plus patients was 94 ± 5% versus 40 ± 10% in MRD intermediate- and 30 ± 14% in high-risk IKZF1 plus patients ( P ≤ .001). Corresponding 5-year cumulative incidence of relapse rates were 6 ± 6%, 60 ± 10%, and 60 ± 17% ( P ≤ .001). Conclusion: IKZF1 plus describes a new MRD-dependent very-poor prognostic profile in BCP ALL. Because current AIEOP-BFM treatment is largely ineffective for MRD-positive IKZF1 plus patients, new experimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.74.3617

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 303

Metadata

Authors
Stanulla, M., Dagdan, E., Zaliova, M., Möricke, A., Palmi, C., Cazzaniga, G., Eckert, C., te Kronnie, G., Bourquin, J.-P., Bornhauser, B., Koehler, R., Bartram, C. R., Ludwig, W.-D., Bleckmann, K., Groeneveld-Krentz, S., Schewe, D., Junk, S. V., Hinze, L., Klein, N., Kratz, C. P., Biondi, A., Borkhardt, A., Kulozik, A., Muckenthaler, M. U., Basso, G., Valsecchi, M. G., Izraeli, S., Petersen, B.-S., Franke, A., Dörge, P., Steinemann, D., Haas, O. A., Panzer-Grümayer, R., Cavé, H., Houlston, R. S., Cario, G., Schrappe, M., Zimmermann, M., for the TRANSCALL Consortium, & the International BFM Study Group
Venue
Journal of Clinical Oncology
Published
2018-04-20
Volume
36
Issue
12
Pages
1240-1249
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2794056739
Cited by
303
References
49
FWCI
26.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IKZF1plusDefines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. https://app.cochat.ai/papers/10.1200/jco.2017.74.3617
The paper
Stanulla, M., Dagdan, E., Zaliova, M., Möricke, A., Palmi, C., Cazzaniga, G., Eckert, C., te Kronnie, G., Bourquin, J.-P., Bornhauser, B., Koehler, R., Bartram, C. R., Ludwig, W.-D., Bleckmann, K., Groeneveld-Krentz, S., Schewe, D., Junk, S. V., Hinze, L., Klein, N., . . . the International BFM Study Group. (2018). IKZF1plusDefines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.74.3617

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.